



US009492491B1

(12) **United States Patent**
Hayer et al.

(10) **Patent No.:** **US 9,492,491 B1**
(45) **Date of Patent:** ***Nov. 15, 2016**

(54) **COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH**

(71) Applicant: **KIDNEY STONE LABORATORIES, INC.**, Fort Lauderdale, FL (US)

(72) Inventors: **Gregory K. Hayer**, Fort Lauderdale, FL (US); **Brendan Magrab**, Westfield, NJ (US); **Henry R. Wolfe, Jr.**, Glenmoore, PA (US)

(73) Assignee: **KIDNEY STONE LABORATORIES, INC.**, Fort Lauderdale, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/059,644**

(22) Filed: **Mar. 3, 2016**

Related U.S. Application Data

(63) Continuation-in-part of application No. 14/960,692, filed on Dec. 7, 2015, which is a continuation of application No. 14/845,612, filed on Sep. 4, 2015, now Pat. No. 9,233,135.

(51) **Int. Cl.**

- A61K 36/00* (2006.01)
- A61K 36/88* (2006.01)
- A61K 9/00* (2006.01)
- A61K 31/194* (2006.01)
- A61K 33/06* (2006.01)
- A61K 31/6615* (2006.01)
- A61K 31/4415* (2006.01)
- A61K 9/48* (2006.01)

(52) **U.S. Cl.**

CPC *A61K 36/88* (2013.01); *A61K 9/0053* (2013.01); *A61K 9/48* (2013.01); *A61K 31/194* (2013.01); *A61K 31/4415* (2013.01); *A61K 31/6615* (2013.01); *A61K 33/06* (2013.01)

(58) **Field of Classification Search**

None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2013/0302448 A1* 11/2013 Parc A23L 1/302
424/725

FOREIGN PATENT DOCUMENTS

RO 80051 A2 * 10/1982

OTHER PUBLICATIONS

Prasobh et al, A study on the use of musa species in the management of renal calculi. Asian Journal of Pharmaceutical and Clinical Research, (Jul.-Sep. 2014) vol. 7, No. 3, pp. 123-125.*

"Complications from kidney stone treatments are common, costly"; Science Daily;Duke University Medical Center;Apr. 2014; <http://www.sciencedaily.com/releases/2014/04/140428094257.htm> [retrieved on Aug. 19, 2015]; 2 pages.

"6 Easy Ways to Prevent Kidney Stones"; National Kidney Foundation; 2015; https://www.kidney.org/atoz/content/kidneystones_prevent [retrieved on Aug. 19, 2015]; 2 pages.

"Diet for Kidney Stone Prevention"; NIH; Feb. 2013,The National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication No. 13-6425, 8 pages.

"How Can Kidney Stones Be Prevented?"; The Johns Hopkins School of Medicine; The James Buchanan Brady Urological Institute;Accessed Aug. 31, 2015; <http://urology.jhu.edu/kidney/STONESprevention.php>; 3 pages.

Allie-Hamdulay; Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial; Urol Res;vol. 33; 2005; pp. 116-124.

Barcelo et al.; "Randomized Double-Blind Study of Potassium Citrate in Idiopathic Hypocitraturic Calcium Nephrolithiasis"; The Journal of Urology, vol. 150; 1993; pp. 1761-1764.

Chow et al.; "Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones"; Kidney International, vol. 65; 2004; pp. 1724-1730.

Chow et al.;"A stone farm: development of a method for simultaneous production of multiple calcium oxalate stones in vitro"; Urol Res, vol. 32; 2004; pp. 55-60.

Coe (2015); "Citrate to Prevent Calcium and Uric Acid Stones"; University of Chicago Kidney Stone Evaluation and Treatment Program; <http://kidneystones.uchicago.edu/citrate-to-prevent-stones/> [retrieved on Aug. 19, 2015];8 pages.

Coe et al.; "The Pathogenesis and Treatment of Kidney Stones"; N. Engl J Med, vol. 327; 1992; pp. 1141-1152 (abstract only).

Costa-Bauza et al.; "Factors affecting calcium oxalate dihydrate fragmented calculi regrowth" BMC Urology,vol. 6, No. 16, 2006; 7 pages.

Ettinger et al.; "Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis"; J Urol., vol. 158; 1997; pp. 2069-2073.

Fabris et al.; "Long-Term Treatment with Potassium Citrate and Renal Stones in Medullary Sponge Kidney"; Clin J Am Soc Nephrol.,vol. 5, No. 9; 2010; pp. 1663-1668.

Forbes et al.; "Effects of Dietary Phytate, Calcium and Magnesium Levels on Zinc Bioavailability to Rats"; J. Nutr., vol. 114; 1984; pp. 1421-1425.

(Continued)

Primary Examiner — Qiuwen Mi

(74) *Attorney, Agent, or Firm* — Cantor Colburn LLP

(57) **ABSTRACT**

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.